PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17
Phase 1
Completed
- Conditions
- Neutropenia
- First Posted Date
- 2003-03-12
- Last Posted Date
- 2008-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT00056381
- Locations
- 🇺🇸
Versicor, King of Prussia, Pennsylvania, United States
Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer
Phase 2
Completed
- Conditions
- Kidney Neoplasms
- First Posted Date
- 2003-02-13
- Last Posted Date
- 2007-05-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 63
- Registration Number
- NCT00054886
- Locations
- 🇺🇸
Pfizer Investigational Site, Madison, Wisconsin, United States
Four-Drug Combination Treatment in Hiv-Infected Subjects Failing Therapy With Antiretroviral Regimens
Phase 2
Completed
- Conditions
- HIV Infections
- First Posted Date
- 2003-01-23
- Last Posted Date
- 2007-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 300
- Registration Number
- NCT00052117
Capravirine (AG1549) in Combination With Viracept and Two NRTIs in HIV Infected Patients Who Failed an Initial NNRTI Containing Regimen
Phase 2
Completed
- Conditions
- Human Immunodeficiency Virus
- First Posted Date
- 2003-01-20
- Last Posted Date
- 2011-05-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 179
- Registration Number
- NCT00051844
- Locations
- 🇪🇸
Pfizer Investigational Site, Cordoba, Spain
A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer
Phase 2
Completed
- Conditions
- Breast Neoplasms
- First Posted Date
- 2003-01-03
- Last Posted Date
- 2007-05-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 168
- Registration Number
- NCT00051051
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer
Phase 2
Completed
- Conditions
- Lung Neoplasms
- First Posted Date
- 2002-12-24
- Last Posted Date
- 2006-11-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 163
- Registration Number
- NCT00050830
- Locations
- 🇬🇧
Pfizer Investigational Site, London, United Kingdom
Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia Requiring Mechanical Ventilatory Support
Phase 3
Completed
- Conditions
- Pneumonia
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 500
- Registration Number
- NCT00050401
Treatment of Pediatric Hypertension With Altace Trial
Phase 4
Completed
- Conditions
- Hypertension
- First Posted Date
- 2002-08-26
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 310
- Registration Number
- NCT00044265
- Locations
- 🇺🇸
Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸PCTI at Columbus Children's Hospital, Columbus, Ohio, United States
🇺🇸The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer
Phase 2
Completed
- Conditions
- Carcinoma, Breast
- Interventions
- Drug: 0.08 mg/kg CpG 7909Drug: 0.04 mg/kg CpG 7909Drug: 0.12 mg/kg CpG 7909Drug: 0.16 mg/kg CpG 7909
- First Posted Date
- 2002-08-12
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT00043394
- Locations
- 🇺🇸
Pfizer Investigational Site, Burlington, Vermont, United States
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)
Phase 2
Completed
- Conditions
- MelanomaBreast NeoplasmsCarcinoma, Renal CellLymphoma, T-CellCarcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2002-08-12
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 31
- Registration Number
- NCT00043368
- Locations
- 🇩🇪
Pfizer Investigational Site, Koeln, Germany
© Copyright 2025. All Rights Reserved by MedPath